AYTU
Aytu BioPharma, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-31/100
Last price
2.05
▲ 0.01 (0.49%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.05
Prev close
2.04
Day high
2.09
Day low
2.02
Volume
21.62K
Market cap
$22.28M
P/E (TTM)
—
52W range
1.80 – 3.07
Day trading desk
Gap from prior close
+0.49%
Prior close 2.04
VWAP
2.05
-0.05% from price
Relative volume
0.65×
Normal
Session range
3.47%
2.02 – 2.09
Position in range
43%
Mid range
ATR (14D)
0.12
5.99% of price
Prior day high
2.15
PDH
Prior day low
2.04
PDL
Bid / ask spread
—
Quote not published
Session volume
22.72K
Avg 34.93K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.82%
-8.8%
1M
-7.24%
-8.4%
3M
-5.96%
-10.5%
6M
-20.23%
-38.4%
YTD
-21.15%
-35.4%
1Y
+7.89%
-8.5%
3Y
-24.07%
-106.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AYTU open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
887.27K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 28, 26 | DISBROW JOSHUA R. Chief Executive Officer |
STOCK | 30.00K | $0 | Direct |
| Jul 28, 26 | DOCKERY CARL C Director |
STOCK | 10.00K | $0 | Direct |
| Jul 28, 26 | DISBROW JARRETT T Officer |
STOCK | 15.00K | $0 | Direct |
| Jul 28, 26 | SELHORN RYAN J Chief Financial Officer |
STOCK | 25.00K | $0 | Direct |
| Jul 28, 26 | PYSZCZYMUKA GREG Officer |
STOCK | 20.00K | $0 | Direct |
| Jul 28, 26 | JAIN ABHINAV Director |
STOCK | 10.00K | $0 | Direct |
| Jul 28, 26 | LIU VIVIAN H Director |
STOCK | 10.00K | $0 | Direct |
| Oct 3, 25 | DISBROW JOSHUA R. Chief Executive Officer |
STOCK | 53.95K | $0 | Direct |
| Oct 3, 25 | DOCKERY CARL C Director |
STOCK | 10.00K | $0 | Direct |
| Oct 3, 25 | DISBROW JARRETT T Officer |
STOCK | 32.11K | $0 | Direct |
| Oct 3, 25 | SELHORN RYAN J Chief Financial Officer |
STOCK | 33.74K | $0 | Direct |
| Oct 3, 25 | PYSZCZYMUKA GREG Officer |
STOCK | 12.50K | $0 | Direct |
| Oct 3, 25 | JAIN ABHINAV Director |
STOCK | 10.00K | $0 | Direct |
| Oct 3, 25 | LIU VIVIAN H Director |
STOCK | 10.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
DISBROW JARRETT T |
Officer | 76.57K | Stock Award(Grant) |
DISBROW JOSHUA R. |
Chief Executive Officer | 237.20K | Stock Award(Grant) |
DOCKERY CARL C |
Director | 31.15K | Stock Award(Grant) |
JAIN ABHINAV |
Director | 29.50K | Stock Award(Grant) |
LIU VIVIAN H |
Director | 29.82K | Stock Award(Grant) |
PYSZCZYMUKA GREG |
Officer | 56.10K | Stock Award(Grant) |
SELHORN RYAN J |
Chief Financial Officer | 74.74K | Stock Award(Grant) |
Fundamentals
Market cap$22.28M
Enterprise value$14.07M
Revenue (TTM)$57.57M
Gross profit$36.82M
EBITDA$-4.38M
Net income$-14.25M
EPS (TTM)$-1.16
Free cash flow$5.60M
Total cash$26.31M
Total debt$18.11M
Book value / share$3.29
Shares outstanding10.87M
Float7.69M
Short % of float3.33%
Dividend yield0.00%
Beta (5Y)0.18
Valuation & profitability ratios
Trailing P/E—
Forward P/E13.23
PEG ratio—
Price / sales—
Price / book0.62
EV / revenue0.24
EV / EBITDA-3.21
Gross margin63.95%
Operating margin-4.82%
Profit margin-24.76%
Return on equity-52.55%
Return on assets-4.54%
Debt / equity51.33
Current ratio1.13
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Total revenue | $57.57M | $66.38M | $65.18M | $107.40M | -13.3% |
| Operating revenue | $57.57M | $66.38M | $65.18M | $107.40M | -13.3% |
| Cost of revenue | $20.75M | $20.55M | $16.13M | $40.77M | +1.0% |
| Gross profit | $36.82M | $45.83M | $49.05M | $66.63M | -19.7% |
| Research & development | $0 | $1.33M | $2.77M | $4.09M | -100.0% |
| Selling, general & admin | $42.64M | $38.28M | $42.04M | $70.08M | +11.4% |
| Total operating expense | $45.13M | $43.29M | $48.49M | $78.96M | +4.2% |
| Operating income | -$8.31M | $2.54M | $565.00K | -$12.33M | -427.7% |
| Net interest income | -$1.90M | -$3.70M | -$5.06M | -$4.96M | +48.8% |
| Pre-tax income | -$14.23M | -$13.74M | -$10.38M | -$17.05M | -3.5% |
| Tax provision | $21.00K | $437.00K | $2.14M | $0 | -95.2% |
| Net income | -$14.25M | -$13.56M | -$15.84M | -$17.05M | -5.1% |
| Net income to common | -$14.25M | -$13.56M | -$15.84M | -$17.05M | -5.1% |
| Basic EPS | -1.16 | -2.16 | -2.86 | -5.11 | +46.3% |
| Diluted EPS | -1.16 | -2.16 | -2.86 | -5.11 | +46.3% |
| EBIT | -$12.34M | -$10.04M | -$5.32M | -$12.09M | -22.8% |
| EBITDA | -$8.41M | -$4.67M | $1.41M | -$3.27M | -80.2% |
| Basic shares | 12.32M | 6.28M | 5.54M | 3.34M | +96.2% |
| Diluted shares | 12.32M | 6.28M | 5.54M | 3.34M | +96.2% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $26.31M | $30.95M | $20.01M | $22.98M | -15.0% |
| Cash & short-term investments | $26.31M | $30.95M | $20.01M | $22.98M | -15.0% |
| Accounts receivable | $22.78M | $31.16M | $23.53M | $28.94M | -26.9% |
| Inventory | $6.86M | $11.43M | $12.14M | $11.99M | -40.0% |
| Total current assets | $61.76M | $79.18M | $61.89M | $71.08M | -22.0% |
| Property, plant & equipment | $1.24M | $1.59M | $1.52M | $3.87M | -22.0% |
| Goodwill & intangibles | $41.40M | $42.20M | $52.45M | $58.97M | -1.9% |
| Total assets | $105.01M | $124.18M | $118.09M | $136.46M | -15.4% |
| Total current liabilities | $54.66M | $63.06M | $62.23M | $69.02M | -13.3% |
| Current debt | $7.93M | $10.92M | $4.25M | $1.65M | -27.4% |
| Long-term debt | $9.10M | $10.89M | $10.88M | $14.71M | -16.5% |
| Total debt | $17.03M | $21.82M | $15.13M | $16.36M | -21.9% |
| Total liabilities | $69.73M | $105.21M | $90.38M | $97.11M | -33.7% |
| Retained earnings | -$347.79M | -$333.54M | -$319.97M | -$304.13M | -4.3% |
| Shareholder equity | $35.27M | $18.97M | $27.72M | $39.36M | +86.0% |
| Working capital | $7.10M | $16.11M | -$337.00K | $2.06M | -55.9% |
| Net tangible assets | -$6.13M | -$23.23M | -$24.74M | -$19.61M | +73.6% |
| Shares issued | 10.73M | 8.98M | 5.97M | 5.52M | +19.6% |
| Line item | 2026 | 2025 | 2024 | 2023 | YoY |
|---|---|---|---|---|---|
| Net income | -$14.25M | -$13.56M | -$15.84M | -$17.05M | -5.1% |
| Depreciation & amortisation | $3.93M | $5.38M | $6.72M | $8.81M | -26.9% |
| Stock-based compensation | $691.00K | $576.00K | $2.37M | $6.05M | +20.0% |
| Change in working capital | $5.83M | -$5.73M | -$4.66M | -$5.80M | +201.8% |
| Operating cash flow | $3.28M | -$1.94M | -$1.39M | -$5.13M | +269.4% |
| Capital expenditure | -$29.00K | -$3.23M | -$329.00K | — | +99.1% |
| Investing cash flow | -$29.00K | -$2.56M | -$329.00K | -$117.00K | +98.9% |
| Financing cash flow | -$7.90M | $15.44M | -$1.26M | $8.87M | -151.1% |
| Free cash flow | $3.25M | -$5.17M | -$1.72M | -$5.13M | +163.0% |
| End cash position | $26.31M | $30.95M | $20.01M | $22.98M | -15.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $16.11M | $12.41M | $15.16M | $13.89M | $15.13M | — | +29.8% |
| Operating revenue | $16.14M | $12.41M | $15.16M | $13.89M | $15.13M | — | +30.1% |
| Cost of revenue | $5.70M | $4.81M | $5.54M | $4.70M | $4.88M | — | +18.4% |
| Gross profit | $10.41M | $7.60M | $9.62M | $9.19M | $10.25M | — | +37.0% |
| Research & development | $0 | $0 | $0 | $0 | $216.00K | — | — |
| Selling, general & admin | $10.43M | $10.90M | $11.07M | $10.25M | $8.48M | — | -4.4% |
| Total operating expense | $11.19M | $11.66M | $11.59M | $10.69M | $9.61M | — | -4.1% |
| Operating income | -$777.00K | -$4.06M | -$1.97M | -$1.50M | $640.00K | — | +80.9% |
| Net interest income | -$383.00K | -$436.00K | -$560.00K | -$516.00K | -$730.00K | — | +12.2% |
| Pre-tax income | -$4.00K | -$5.61M | -$10.58M | $1.97M | -$19.44M | — | +99.9% |
| Tax provision | $11.00K | $10.00K | $0 | $0 | $437.00K | — | +10.0% |
| Net income | -$15.00K | -$5.62M | -$10.58M | $1.97M | -$19.82M | — | +99.7% |
| Net income to common | -$15.00K | -$5.62M | -$10.58M | $1.97M | -$19.82M | — | +99.7% |
| Basic EPS | 0.00 | -0.53 | -1.05 | 0.21 | — | 0.65 | +100.0% |
| Diluted EPS | -0.00 | -0.53 | -1.05 | -0.08 | — | 0.21 | +99.9% |
| EBIT | $379.00K | -$5.17M | -$10.02M | $2.48M | -$18.71M | — | +107.3% |
| EBITDA | $1.50M | -$4.05M | -$9.14M | $3.28M | -$17.42M | — | +137.0% |
| Basic shares | 19.32M | 10.51M | 10.04M | 9.44M | — | 6.13M | +83.8% |
| Diluted shares | 19.32M | 10.51M | 10.04M | 19.48M | — | 8.20M | +83.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.31M | $26.71M | $30.02M | $32.63M | $30.95M | -1.5% |
| Cash & short-term investments | $26.31M | $26.71M | $30.02M | $32.63M | $30.95M | -1.5% |
| Accounts receivable | $22.78M | $24.49M | $30.92M | $33.23M | $31.16M | -7.0% |
| Inventory | $6.86M | $7.46M | $8.66M | $10.10M | $11.43M | -8.0% |
| Total current assets | $61.76M | $67.33M | $76.24M | $81.11M | $79.18M | -8.3% |
| Property, plant & equipment | $1.24M | $1.32M | $1.44M | $1.51M | $1.59M | -5.7% |
| Goodwill & intangibles | $41.40M | $42.49M | $43.58M | $41.43M | $42.20M | -2.6% |
| Total assets | $105.01M | $111.69M | $122.00M | $124.99M | $124.18M | -6.0% |
| Total current liabilities | $54.66M | $59.97M | $65.56M | $65.99M | $63.06M | -8.9% |
| Current debt | $7.93M | $12.27M | $10.93M | $16.73M | $10.92M | -35.4% |
| Long-term debt | $9.10M | $9.55M | $10.00M | $10.45M | $10.89M | -4.7% |
| Total debt | $17.03M | $21.82M | $20.93M | $27.18M | $21.82M | -21.9% |
| Total liabilities | $69.73M | $76.55M | $107.80M | $101.82M | $105.21M | -8.9% |
| Retained earnings | -$347.79M | -$347.77M | -$342.15M | -$331.57M | -$333.54M | -0.0% |
| Shareholder equity | $35.27M | $35.14M | $14.20M | $23.17M | $18.97M | +0.4% |
| Working capital | $7.10M | $7.35M | $10.68M | $15.12M | $16.11M | -3.4% |
| Net tangible assets | -$6.13M | -$7.35M | -$29.38M | -$18.26M | -$23.23M | +16.6% |
| Shares issued | 10.73M | 10.73M | 10.73M | 9.91M | 8.98M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$15.00K | -$5.62M | -$10.58M | $1.97M | -$19.82M | — | +99.7% |
| Depreciation & amortisation | $1.12M | $1.12M | $885.00K | $803.00K | $1.29M | — | 0.0% |
| Stock-based compensation | $146.00K | $148.00K | $283.00K | $114.00K | $113.00K | — | -1.4% |
| Change in working capital | $3.69M | -$1.81M | $3.98M | -$23.00K | $1.64M | — | +303.3% |
| Operating cash flow | $4.41M | -$4.18M | $3.67M | -$618.00K | $2.80M | — | +205.4% |
| Capital expenditure | -$12.00K | — | — | — | -$3.02M | -$69.00K | — |
| Investing cash flow | -$12.00K | $0 | -$17.00K | $0 | -$3.02M | — | — |
| Financing cash flow | -$4.80M | $872.00K | -$6.26M | $2.30M | $12.99M | — | -650.6% |
| Free cash flow | $4.39M | -$4.18M | $3.66M | -$618.00K | -$214.00K | — | +205.1% |
| End cash position | $26.31M | $26.71M | $30.02M | $32.63M | $30.95M | — | -1.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.35 | -0.06 | +82.7% |
| Mar 2026 | -0.43 | -0.41 | +2.4% |
| Dec 2025 | -0.50 | -0.23 | +52.9% |
| Sep 2025 | -0.20 | -0.09 | +52.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.18 | 2 | $13.27M | -4.4% |
| Next quarter | -0.14 | 2 | $15.28M | +0.8% |
| Current year | -0.37 | 2 | $67.91M | +18.0% |
| Next year | 0.16 | 2 | $86.91M | +28.0% |
Analyst targets & ownership
Mean target$9.67
High target$15.00
Low target$7.00
Implied upside371.54%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders8.16%
Held by institutions35.51%
Institutions holding45
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.16
-5.22% from price
SMA 20
2.11
-2.91% from price
SMA 50
2.22
-7.47% from price
SMA 100
2.20
-6.79% from price
SMA 200
2.38
-13.73% from price
EMA 12
2.12
-3.33% from price
EMA 26
2.15
-4.76% from price
EMA 50
2.19
-6.18% from price
RSI (14)
40.6
Neutral
MACD (12,26,9)
-0.03
Hist -0.01
ATR (14)
0.12
5.99% of price
Realised vol 30D
38.1%
Annualised
Bollinger upper
2.32
20, 2σ
Bollinger lower
1.91
20, 2σ
50 / 200 cross
Death
2.22 vs 2.38
Trend bias
Below 200
-13.73%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.75
Less volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
38.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-32.1%
Peak to trough
Max drawdown 5Y
-98.2%
Peak to trough
ATR 14
0.12
5.99% of price
Beta (reported)
0.18
5Y monthly, from filing
Short interest
Shares short
311.61K
Prior 321.54K
Change vs prior
-3.1%
Shorts covering
% of float
3.33%
Normal
% of shares out
2.87%
Against total outstanding
Days to cover
12.1
Crowded exit
Float
7.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 30, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jun 11, 26 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Dec 10, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Sep 25, 25 | Maxim Group | MAINTAINED | Buy | Buy |
| Sep 25, 25 | Ascendiant Capital | MAINTAINED | Buy | Buy |
| Jul 1, 25 | Lake Street | INITIATED | — | Buy |
| Jun 30, 25 | Ascendiant Capital | INITIATED | — | Buy |
| Aug 9, 23 | Maxim Group | INITIATED | — | Buy |
| May 31, 23 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay dateDec 9, 2020
Last split1:20
Split dateJan 6, 2023
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-22
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-05-13
Corporate Changes & Voting Matters
8-K · 2026-04-02
Periodic Financial Reports
10-Q · 2026-02-03
Corporate Changes & Voting Matters
8-K · 2026-01-20
Corporate Changes & Voting Matters
8-K · 2025-12-10
Corporate Changes & Voting Matters
8-K · 2025-11-13
Headlines
Aytu BioPharma, Inc. Q4 2026 Earnings Call Summary
Moby · 14d ago
Aytu BioPharma Inc (AYTU) (Q4 2026) Earnings Call Highlights: EXXUA Launch Accelerates as ...
GuruFocus.com · 14d ago
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Zacks · 14d ago
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
ACCESS Newswire · 14d ago
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
ACCESS Newswire · 20d ago
HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
Zacks · 22d ago
New Strong Sell Stocks for July 20th
Zacks · 79d ago
New Strong Sell Stocks for July 16th
Zacks · 83d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.